陈 瑞,杨 丽,张小茜.嵌合抗原受体修饰T细胞在多形性胶质母细胞瘤中的应用及其研究进展[J].肿瘤学杂志,2020,26(2):2-139. |
嵌合抗原受体修饰T细胞在多形性胶质母细胞瘤中的应用及其研究进展 |
Progress on Application of Chimeric Antigen Receptor Modified T Cells(CAR?鄄T) Therapy in Glioblastoma |
投稿时间:2019-05-15 |
DOI:10.11735/j.issn.1671-170X.2020.02.B012 |
|
|
|
中文关键词: 多形性胶质母细胞瘤 嵌合抗原受体 免疫治疗 |
英文关键词:glioblastoma chimeric antigen receptor immunotherapy |
基金项目: |
|
摘要点击次数: 1205 |
全文下载次数: 306 |
中文摘要: |
摘 要:多形性胶质母细胞瘤(glioblastoma multiforme,GBM)是成人最常见也是恶性程度最高的颅内原发肿瘤,其侵袭性强、进展迅速。尽管现已有标准的手术加放化疗综合治疗策略,但其预后效果仍然不佳。近年来,随着肿瘤免疫治疗的不断探索,越来越多的免疫治疗方法有望应用到胶质瘤患者中。全文将对现兴起的GBM疗法——嵌合抗原受体修饰T细胞(chimeric antigen receptor engineered T cells,CAR?鄄T)疗法进行详解,并对其应用到临床GBM患者存在的问题作一总结。 |
英文摘要: |
Abstract:Glioblastoma multiforme(GBM) is the most common intracranial primary malignant tumor in adults,and it has the characteristics of strong invasion and rapid progress. Surgery combined with radiotherapy or chemotherapy is the standard therapeutic strategy for GBM,but the outcomes is still poor. In recent years,more and more methods of immunotherapy are applied to glioma patients. In this article we review the application of a newly emerging immunotherapy chimeric antigen receptor engineered T cells(CAR-T therapy) in treatment of GBM patients and related challenges. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |